LinkedIn facebook twitter youtube
News archive
Recent news

MMPredict is a HORIZON 2020 project, which Myeloma Patients Europe (MPE) is involved in, aimed at clinically validating a personalised medicines tool that predicts the most effective treatment options for myeloma patients.

As part of MMPredict, MPE has been involved in the development and dissemination of a survey  assessing the quality of life of European myeloma patients, particularly relating to currently available myeloma treatments and how side-effects impact upon them.

MPE along with all stakeholders involved in this project, developed the survey based on the EQ5D quality of life tool, and EORTC QLQ-30, supplemented with EORTC multiple myeloma module QLQ-20. There were also a number of additional questions added by the project team. The survey was run primarily in the following European countries: UK, The Netherlands, Italy and Germany.

The results of this research were presented at the 24th European Hematology Association (EHA) Congress which was held in Amsterdam, The Netherlands, from 13 to 16 June 2019.

The main author of this research, Annemieke Van Dongen-Leunis, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, explains the main results of the survey in the video below.



The MMPredict consortium also presented further research at EHA congress aimed at analysing the cost-effectiveness of risk stratified treatment in transplant eligible patients. Annemieke Van Dongen-Leunis, the main author of this research, explains the main results in the video below.



Along with MPE, the consortium of European partners includes Skyline, Erasmus MC (EMC, Rotterdam), University of Turin (Unito, Turin) and the Institute for Medical Technology Assessment (iMTA, Rotterdam). You can read more about MMPredict here.


This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 701143


Recent news

» MPE Publishes 2021: Year in Review

» ASH 2021| over 50% of myeloma patients reach minimal residual disease negativity with Isatuximab in combination with RVd

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy